American Society for Preventive Cardiology | Strategic Alliance Partners

Robert Kushner, MD: An Emphasis on Obesity as CV Risk Factor

July 31st 2022

At the 2022 ASPC annual meeting, Dr. Gluckman highlights the overall impact of the economic cost of cardiovascular disease and the role of prevention.

2022 ASPC Congress on CVD Prevention Live in Louisville, KY from July 29-31

July 30th 2022

Dr. Kushner discusses obesity as a risk factor for CVD and how preventive cardiologists can better target weight management to support patient health.

By HCPLive Editorial Staff

July 22nd 2022

The 2022 scientific sessions in Louisville, Kentucky will emphasize inclusiveness and the care for all at risk for cardiovascular disease.

ASPC Announces Official Program Covering the ABCs of Preventive Cardiology at Premier Annual Congress on CVD Prevention

June 29th 2022

Seth Martin, MD: Patient Confidence and Emerging Smartphone Technology

Ty Gluckman, MD: Disparities in Care Despite Increased Technology Use

Dr. Martin explains the connection between inclusive cardiology technology and patient care and confidence.

Marc Bonaca, MD: Personalizing Therapy in Peripheral Artery Disease Patients

In part 2 of an interview with HCPLive, Ty Gluckman, MD discusses both the advantages and disadvantages of technology replacing traditional care.

Seth Martin, MD: Cardiologists Should “Think Big” About New Technologies

Marc Bonaca, MD discusses the personalization of treatment in PAD patients, lack of proper research into the condition, and optimizing delivery of care.

Ty Gluckman, MD: Utilizing Advances in Technology for Cardiovascular Care

Advancements in technology and the availability of resources for patients and doctors alike could mean a bright future for cardiology research.

Harold Bays, MD: Exploring Benefits and Outcomes of GLP-1 RA Treatment

Ty Gluckman, MD speaks on the use of medical technology, including wearables and and telemedicine, and the growing importance of mobile health.

Pam Taub, MD: The Implication of Diet and Socioeconomic Status in CVD Management

Harold Bays, MD discussed the effectiveness of GLP-1 RA in treatment, as well as the development of oral semaglutide.

Peter Toth, MD: Facing Complications in Lipid Management

Dr. Taub speaks on the technology-based advancements in cardiovascular care and socioeconomic status can affect a patient’s diet and access to care.

Pam Taub, MD: Healthy Lifestyle Programs for Patients with CVD

Peter Toth, MD discusses the combination treatment aspects of lipid management agents, as well as the effect of the COVID-19 pandemic on cardiovascular care.

Peter Toth, MD: Innovative Approaches to Lipid Management

Dr. Pam Taub speaks on the misconceptions of cardiac rehabilitation and other lifestyle approaches recommended for patients with cardiovascular diseases.